C. Kell

A Phase 2 Randomized Controlled Study of Tralokinumab in Subjects with Idiopathic Pulmonary Fibrosis

K. Flaherty, L. Lancaster, I. Glaspole, 2018, American journal of respiratory and critical care medicine.

Pharmacokinetics, Pharmacodynamics, and Safety of MEDI4212, an Anti-IgE Monoclonal Antibody, in Subjects with Atopy: A Phase I Study

M. Schwickart, Keunpyo Kim, E. Sheldon, 2016, Advances in Therapy.

Treatment of atopic dermatitis with tralokinumab, an anti–IL‐13 mAb

J. Silverberg, A. Wollenberg, K. Ranade, 2019, The Journal of allergy and clinical immunology.

A Phase 2b Dose-Ranging Efficacy and Safety Study of Tralokinumab in Adult Patients with Moderate to Severe Atopic Dermatitis

J. Silverberg, A. Wollenberg, K. Ranade, 2018 .

A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma

C. Brightling, R. Faggioni, E. Piper, 2012, European Respiratory Journal.

Phase 2 randomized, double-blind, placebo-controlled study of tralokinumab, an anti-IL-13 monoclonal antibody, in moderate to severe asthma

C. Brightling, R. Faggioni, E. Piper, 2011 .

Proof of Mechanism for Anti-Interleukin-33 Antibody Tozorakimab in a Phase 1 Study in Healthy Adults and Patients with Chronic Obstructive Pulmonary Disease

H. Killick, C. Kell, N. White, 2022, B21. BASIC, CLINICAL, AND TRANSLATIONAL COPD STUDIES: THE ONGOING HUNT FOR UNDERLYING MECHANISMS AND THERAPEUTIC TARGETS.

Safety, Pharmacokinetics and Immunogenicity of the Anti-Interleukin-33 Antibody, Tozorakimab: Results of a Phase 1 Study in Healthy Adults and Patients with Chronic Obstructive Pulmonary Disease

D. Singh, R. Moate, E. Jiménez, 2022, B21. BASIC, CLINICAL, AND TRANSLATIONAL COPD STUDIES: THE ONGOING HUNT FOR UNDERLYING MECHANISMS AND THERAPEUTIC TARGETS.

A randomised phase 2a study to investigate the effects of blocking interleukin-33 with tozorakimab in patients hospitalised with COVID-19: ACCORD-2

M. Shankar-Hari, H. Pandya, D. Saralaya, 2023, ERJ open research.